Product Description
Mechanisms of Action: Iodine Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Australia | Austria | Bangladesh | Cyprus | Denmark | Dominican Republic | Egypt | Finland | France | Greece | Hong Kong | Iceland | India | Indonesia | Ireland | Jordan | Korea | Malaysia | Malta | Morocco | Netherlands | New Zealand | Norway | Pakistan | Philippines | Saudi Arabia | Singapore | South Africa | Spain | Sri Lanka | Switzerland | Taiwan | Ukraine | United Arab Emirates | United Kingdom | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Newcastle-upon-Tyne Hospitals NHS Trust
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Graves Disease
Phase 3: Thyrotoxicosis|Graves Disease|Hyperthyroidism
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TRIBUTE | N/A |
Completed |
Hyperthyroidism |
2023-05-19 |
|
COVID-19 | N/A |
Completed |
Severe Acute Respiratory Syndrome|COVID-19|Hypothyroidism|Hyperthyroidism |
2021-09-30 |
|
ChoPS | P3 |
Unknown status |
Hyperthyroidism|Graves Disease |
2018-03-01 |
|
ACTRN12615000362594 | P4 |
Terminated |
Graves Disease |
2016-09-06 |